Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Avigen Board Survives Proxy Fight But Company Will Liquidate Holdings

This article was originally published in The Pink Sheet Daily

Executive Summary

In abandoning its efforts to find a buyer, troubled biotech promises shareholders a return of at least $1.20 per share.

You may also be interested in...



Frayed Deals, Fraught Partners: Product Tweaks Complicate Agreements

Sub-licenses with universities can make headaches, too, as contracts come “out of the drawer” for closer scrutiny in hard times, panelists agree at recent Napa conference.

Frayed Deals, Fraught Partners: Product Tweaks Complicate Agreements

Sub-licenses with universities can make headaches, too, as contracts come “out of the drawer” for closer scrutiny in hard times, panelists agree at recent Napa conference.

Proxy War-Front Latest: Amylin, Vanda Rocked By Dissident Shareholders

In tough times, patience for failing drugs and restructuring programs wears particularly thin.

Related Content

Topics

UsernamePublicRestriction

Register

PS017586

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel